Mucosal transcriptomics implicates under expression of BRINP3 in the pathogenesis of ulcerative colitis

Inflammatory Bowel Diseases

Volumn 20, Issue 10, 2014, Pages 1802-1812

  Smith, Philip J ^a,b   Levine, Adam P ^a   Dunne, Jenny ^a   Guilhamon, Paul ^c   Turmaine, Mark ^d   Sewell, Gavin W ^a   O'Shea, Nuala R ^a,b   Vega, Roser ^b   Paterson, Jennifer C ^c   Oukrif, Dahmane ^c   Beck, Stephan ^c   Bloom, Stuart L ^b   Novelli, Marco ^c   Rodriguez Justo, Manuel ^c   Smith, Andrew M ^d   Segal, Anthony W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Colon; Inflammatory bowel disease; Methylation; Microarray

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RETINOIC ACID INDUCIBLE NEURAL SPECIFIC 3; GENOMIC DNA; MESSENGER RNA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; FAM5C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLON MUCOSA; COLONOSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROHN DISEASE; DNA METHYLATION; ENDOSCOPIC BIOPSY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; RECTUM BIOPSY; TRANSCRIPTOMICS; ULCERATIVE COLITIS; ADOLESCENT; CASE CONTROL STUDY; DNA MICROARRAY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; INTESTINE MUCOSA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 84910131267     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000169     Document Type: Article

References (63)

1. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
4. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260-266.
5. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
6. Allan A, Bristol JB, Williamson RC. Crypt cell production rate in ulcerative proctocolitis: differential increments in remission and relapse. Gut. 1985;26:999-1003.
7. Eastwood GL, Trier JS. Epithelial cell renewal in cultured rectal biopsies in ulcerative colitis. Gastroenterology. 1973;64:383-390.
8. Serafini EP, Kirk AP, Chambers TJ. Rate and pattern of epithelial cell proliferation in ulcerative colitis. Gut. 1981;22:648-652.
9. Gibson PR, Van De Pol E, Barratt PJ, et al. Ulcerative colitis-a disease characterised by the abnormal colonic epithelial cell? Gut. 1988;29:516-521.
10. Gitter AH, Wullstein F, Fromm M, et al. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology. 2001;121:1320-1328.
11. Oshima T, Miwa H, Joh T. Changes in the expression of claudins in active ulcerative colitis. J Gastroenterol Hepatol. 2008;23(suppl 2):S146-S150.
12. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999;116:301-309.
13. Van Klinken BJ, Van Der Wal JW, Einerhand AW, et al. Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. Gut. 1999;44:387-393.
14. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003;124:1265-1276.
15. Brant SR. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis. 2011;17:1-5.
16. Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology. 2013;145:293-308.
17. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
18. Karayiannakis AJ, Syrigos KN, Efstathiou J, et al. Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. J Pathol. 1998;185:413-418.
19. Schmehl K, Florian S, Jacobasch G, et al. Deficiency of epithelial basement membrane laminin in ulcerative colitis affected human colonic mucosa. Int J Colorectal Dis. 2000;15:39-48.
20. Wheeler JM, Kim HC, Efstathiou JA, et al. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut. 2001;48:367-371.
21. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612-1619.
22. Olsen J, Gerds TA, Seidelin JB, et al. Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. Inflamm Bowel Dis. 2009;15:1032-1038.
23. Clark PM, Dawany N, Dampier W, et al. Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases. Inflamm Bowel Dis. 2012;18:2315-2333.
24. Dieckgraefe BK, Stenson WF, Korzenik JR, et al. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics. 2000;4:1-11.
25. Kim M, Lee S, Yang SK, et al. Differential expression in histologically normal crypts of ulcerative colitis suggests primary crypt disorder. Oncol Rep. 2006;16:663-670.
26. Noble CL, Abbas AR, Cornelius J, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut. 2008;57:1398-1405.
27. Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol. 2011;106:1272-1280.
28. Wu F, Dassopoulos T, Cope L, et al. Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis. 2007;13:807-821.
29. Planell N, Lozano JJ, Mora-Buch R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut. 2013;62:967-976.
30. Amasheh S, Fromm M, Gunzel D. Claudins of intestine and nephron-a correlation of molecular tight junction structure and barrier function. Acta Physiol (Oxf). 2011;201:133-140.
31. Amasheh S, Milatz S, Krug SM, et al. Na+ absorption defends from paracellular back-leakage by claudin-8 upregulation. Biochem Biophys Res Commun. 2009;378:45-50.
32. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007;56:61-72.
33. Poritz LS, Harris LR III, Kelly AA, et al. Increase in the tight junction protein claudin-1 in intestinal inflammation. Dig Dis Sci. 2011;56:2802-2809.
34. Rosenthal R, Milatz S, Krug SM, et al. Claudin-2, a component of the tight junction, forms a paracellular water channel. J Cell Sci. 2010;123:1913-1921.
35. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
36. Harvey RF, Bradshaw MJ. Measuring Crohn's disease activity. Lancet. 1980;1:1134-1135.
37. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
38. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404-409.
39. Tanaka M, Saito H, Kusumi T, et al. Spatial distribution and histogenesis of colorectal Paneth cell metaplasia in idiopathic inflammatory bowel disease. J Gastroenterol Hepatol. 2001;16:1353-1359.
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative the PCR and 2 (-Delta Delta C (T)) method. Methods. 2001;25:402-408.
41. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185-193.
42. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
43. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067-2075.
44. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118-127.
45. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological). 1995;57:289-300.
46. Brown M. A method for combining non-independent, one-sided tests of significance. Biometrics. 1975;31:987-992.
47. Hess A, Iyer H. Fisher's combined p-value for detecting differentially expressed genes using Affymetrix expression arrays. BMC Genomics. 2007;8:96.
48. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30:207-210.
49. Hasler R, Feng Z, Backdahl L, et al. A functional methylome map of ulcerative colitis. Genome Res. 2012;22:2130-2137.
50. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57.
51. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603-607.
52. Dawson J, Bryant MG, Bloom SR, et al. Subcellular fractionation studies of human rectal mucosa: localization of the mucosal peptide hormones. Clin Sci (Lond). 1980;59:457-462.
53. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
54. Johnson AD, Handsaker RE, Pulit SL, et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008;24:2938-2939.
55. Cooke J, Zhang H, Greger L, et al. Mucosal genome-wide methylation changes in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2128-2137.
56. Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci. 1982;27:533-537.
57. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J. 1956;1:1315-1318.
58. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, et al. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitisassociated colorectal cancer. Am J Gastroenterol. 2010;105:1610-1619.
59. Chen L, Su L, Li J, et al. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis Markers. 2012;32:195-202.
60. Connelly JJ, Shah SH, Doss JF, et al. Genetic and functional association of FAM5C with myocardial infarction. BMC Med Genet. 2008;9:33.
61. Carvalho FM, Tinoco EM, Deeley K, et al. FAM5C contributes to aggressive periodontitis. PLoS One. 2010;5:e10053.
62. Tanaka K, Matsumoto E, Higashimaki Y, et al. FAM5C is a soluble osteoblast differentiation factor linking muscle to bone. Biochem Biophys Res Commun. 2012;418:134-139.
63. Shorts-Cary L, Xu M, Ertel J, et al. Bone morphogenetic protein and retinoic acid-inducible neural specific protein-3 is expressed in gonadotrope cell pituitary adenomas and induces proliferation, migration, and invasion. Endocrinology. 2007;148:967-975.